Hans P, Brichant J F, Pieron F, Pieyns P, Born J D, Lamy M
University Department of Anesthesia and Intensive Care Medicine, CHR de la Citadelle, Liege, Belgium.
J Neurosurg Anesthesiol. 1997 Jan;9(1):3-7.
This study was designed to investigate the relationships among anticonvulsant therapy, plasma alpha 1-acid glycoprotein (AAG) levels, and resistance to vecuronium blockade. Thirty-one patients scheduled for routine neurosurgery were included in the study. The patients were treated (TG; n = 20) with phenytoin (n = 15) and/or carbamazepine (n = 4) and/or phenobarbital (n = 3) for > or = 6 days or were left untreated (UG; n = 11, control group). TG patients were further assigned to one of two subgroups according to the plasma anticonvulsant level measured the day before surgery and found to be within (TGW, n = 10) or below (TGB, n = 10) the therapeutic range. Finally, the 31 patients were divided into two more groups according to their plasma AAG levels: higher than (HAAG, n = 17) or within (NAAG, n = 14) the normal range (25-94 mg dl-1). Anesthesia was induced and maintained with propofol and sufentanil. Muscle relaxation was obtained with vecuronium 0.1 mg kg-1. A train-of-four (TOF) stimulation mode at 2 Hz was applied to the ulnar nerve every 15 s, and neuromuscular transmission was assessed using a TOF-Guard accelograph monitor. Plasma AAG concentrations (means +/- SEM) were 103.7 +/- 7.6 mg dl-1 in TG, 80.7 +/- 6.7 mg dl-1 in UG, 95.9 +/- 13.2 mg dl-1 in TGW, 111.6 +/- 7.6 mg dl-1 in TGB. 114.9 +/- 7.4 mg dl-1 in HAAG, and 71.4 +/- 3.8 mg dl-1 in NAAG groups. The differences in plasma AAG concentrations between UG and TG and between HAAG and NAAG groups were statistically significant. No significant relationship was found between plasma AAG levels and phenytoin concentrations (r = -0.26). The time (mean +/- SEM) to recovery of T1 to 25% of control was significantly shorter in TG (28.2 +/- 1.4 min) than in UG (42.2 +/- 3.1 min) but did not differ significantly according to the plasma anticonvulsant level (27.3 +/- 2.0 min in TGW; 29.1 +/- 1.9 min in TGB) and the plasma AAG level 31.7 +/- 1.9 min in HAAG; 35.3 +/- 3.3 min in NAAG). The time for the TOF ratio to recover to 25% yielded similar profiles and statistical significance levels: TG, 32.9 +/- 2.2 min; UG, 51.2 +/- 4.0 min; TGW, 35.0 +/- 3.9 min; TGB, 30.7 +/- 1.8 min; HAAG, 38.1 +/- 3.1 min; NAAG, 42.0 +/- 4.1 min. We conclude that anticonvulsant therapy induces an increase in plasma AAG independently of the plasma anticonvulsant level. However, duration and recovery of vecuronium blockade do not differ according to plasma AAG levels. Consequently, elevated AAG does not contribute to the resistance to vecuronium blockade induced by anticonvulsants.
本研究旨在探讨抗惊厥治疗、血浆α1-酸性糖蛋白(AAG)水平与维库溴铵阻滞耐药性之间的关系。31例计划接受常规神经外科手术的患者纳入本研究。患者接受苯妥英(n = 15)和/或卡马西平(n = 4)和/或苯巴比妥(n = 3)治疗(治疗组;n = 20)≥6天,或未接受治疗(未治疗组;n = 11,对照组)。治疗组患者根据术前一天测得的血浆抗惊厥药水平进一步分为两个亚组,发现其在治疗范围内(治疗组正常范围组,n = 10)或低于治疗范围(治疗组低水平组,n = 10)。最后,31例患者根据其血浆AAG水平又分为两组:高于正常范围(高AAG组,n = 17)或在正常范围内(正常AAG组,n = 14)(25 - 94 mg dl-1)。采用丙泊酚和舒芬太尼诱导和维持麻醉。静脉注射维库溴铵0.1 mg kg-1以实现肌肉松弛。每15秒对尺神经施加一次2 Hz的四个成串刺激(TOF)模式,并使用TOF-Guard加速度仪监测仪评估神经肌肉传递。治疗组血浆AAG浓度(均值±标准误)为103.7±7.6 mg dl-1,未治疗组为80.7±6.7 mg dl-1,治疗组正常范围组为95.9±13.2 mg dl-1,治疗组低水平组为111.6±7.6 mg dl-1,高AAG组为114.9±7.4 mg dl-1,正常AAG组为71.4±3.8 mg dl-1。未治疗组与治疗组之间以及高AAG组与正常AAG组之间血浆AAG浓度差异具有统计学意义。血浆AAG水平与苯妥英浓度之间未发现显著相关性(r = -0.26)。治疗组T1恢复至对照值25%的时间(均值±标准误)显著短于未治疗组(28.2±1.4分钟比42.2±3.1分钟),但根据血浆抗惊厥药水平(治疗组正常范围组为27.3±2.0分钟;治疗组低水平组为29.1±1.9分钟)和血浆AAG水平(高AAG组为31.7±1.9分钟;正常AAG组为35.3±3.3分钟)无显著差异。TOF比值恢复至25%的时间产生相似的结果和统计学显著性水平:治疗组为32.9±2.2分钟;未治疗组为51.2±4.0分钟;治疗组正常范围组为35.0±3.9分钟;治疗组低水平组为30.7±1.8分钟;高AAG组为38.1±3.1分钟;正常AAG组为42.0±4.1分钟。我们得出结论,抗惊厥治疗可独立于血浆抗惊厥药水平诱导血浆AAG升高。然而,维库溴铵阻滞的持续时间和恢复情况根据血浆AAG水平并无差异。因此,升高的AAG并不导致对抗惊厥药诱导的维库溴铵阻滞的耐药性。